Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

MannKind Corp (NASDAQ:MNKD)

0.6464
Delayed Data
As of Dec 09
 -0.0006 / -0.09%
Today’s Change
0.41
Today|||52-Week Range
2.24
-55.42%
Year-to-Date
Horizon (HZNP) Stock Sinks, Friedreich's Ataxia Study Fails
Dec 09 / Zacks.com - Paid Partner Content
Biotech's Dumbest CEO Moves in 2016
Dec 05 / MotleyFool.com - Paid Partner Content
Theravance Stock Up on Fast Track Status for Velusetrag
Dec 07 / Zacks.com - Paid Partner Content
MannKind (MNKD): Strong Industry, Solid Earnings Estimate Revisions
Dec 01 / Zacks.com - Paid Partner Content
Better Buy: MannKind Corp. vs. Novo Nordisk
Dec 06 / MotleyFool.com - Paid Partner Content
3 Biotech Investing Tips That Could Earn You Thousands
Nov 28 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close0.65
Today’s open0.65
Day’s range0.63 - 0.67
Volume3,831,897
Average volume (3 months)3,913,882
Market cap$309.2M
Dividend yield--
Data as of 4:00pm ET, 12/09/2016

Growth & Valuation

Earnings growth (last year)-78.43%
Earnings growth (this year)+112.45%
Earnings growth (next 5 years)+26.80%
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book--

Competitors

 Today’s
change
Today’s
% change
PRTKParatek Pharmaceutic...+0.25+1.87%
SRNESorrento Therapeutic...-0.05-0.92%
COCPCocrystal Pharma Inc+0.00+0.95%
TRVNTrevena Inc-0.02-0.35%
Data as of 4:00pm ET, 12/09/2016

Financials

Next reporting dateMarch 20, 2017
EPS forecast (this quarter)-$0.04
Annual revenue (last year)$0.00
Annual profit (last year)-$368.4M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
CEO, CFO, Director, VP &
Head-Investor Relations
Matthew J. Pfeffer
Chief Medical Officer &
Vice President
Raymond W. Urbanski
Corporate headquarters
Valencia, California

Forecasts


Search for Jobs